Excerpt from FDA report: (doesn't mean much to me - interpretation anyone?)
1.2. Conclusions on the Substantial Evidence of Effectiveness The placebo-controlled study ACP-2566-003 was an adequate and well-controlled study that supports approval of trofinetide for the treatment of children and adults with Rett syndrome. ACP-2566-003 was a multicenter study that provided reliable and statistically significant evidence that treatment with trofinetide for 3 months demonstrated benefit on the co-primary endpoints of the Rett Syndrome Behavior Questionnaire (RSBQ) and clinician rating of the Clinician Global Impression of Improvement (CGI-I). The study also demonstrated a statistically significant difference favoring trofinetide on the prespecified secondary endpoint of the Communication and Symbolic Behavior Scales Developmental Profile – Infant and Toddler – Social Composite Score (CSBS-DP-IT-SCS). This scale, developed as a screening tool to alert clinicians to potential communication deficits in infants and toddlers, is not fit for purpose for determining a treatment-related benefit in the complex concept of social reciprocity and communication ; however, the finding of a benefit on this endpoint in trofinetide Reference ID: 5139595 (b) (4) Clinical Review Michael A. Dimyan, MD NDA 217026 DAYBUE (Trofinetide) CDER Clinical Review Template 14 Version date: March 8, 2019, for all NDAs and BLAs patients is still supportive of overall effectiveness. Further confirmatory evidence of effectiveness was obtained in study NEU-2566-RETT-002, a multisite Phase 2 single-blind placebo run-in, randomized double-blind, placebo-controlled dose ranging clinical trial. The objective of NEU-2566-RETT-002 was to investigate the safety, tolerability, and pharmacokinetics of treatment with 3 different doses of oral trofinetide in girls ages 5 to 15 with Rett syndrome. A total of 82 subjects were enrolled and five outcome measures explored, but the primary support for effectiveness came from comparison of RSBQ and CGI-I in 24 placebo-treated subjects and 27 subjects receiving 200 mg/kg twice daily of trofinetide. Although formal statistical testing for efficacy was not prespecified, the least square means difference between trofinetide and placebo in RSBQ met nominal significance (p=0.042) as did CGI-I (P=0.029).
- Forums
- ASX - By Stock
- NEU
- Neuren AGM 30th May
Neuren AGM 30th May, page-23
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B |
Open | High | Low | Value | Volume |
$20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1024 | $20.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.53 | 285 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10 | 20.100 |
1 | 480 | 20.080 |
3 | 174 | 20.000 |
1 | 150 | 19.980 |
1 | 434 | 19.940 |
Price($) | Vol. | No. |
---|---|---|
20.570 | 295 | 1 |
20.600 | 4094 | 1 |
20.610 | 13 | 1 |
20.650 | 2488 | 1 |
20.700 | 252 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |